Bekaert - Update on the Liquidity Agreement
Tweet
Share
E-mail
Update on the Liquidity Agreement
Period from 5 September 2024 to 11 September 2024
In relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 25 June 2024, Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 7 500 shares during the period from 5 September 2024 to 11 September 2024 on Euronext Brussels. During the same period, Kepler Cheuvreux on behalf of Bekaert has sold 1 800 shares on Euronext Brussels.
The tables below provide an overview of the transactions under the liquidity agreement during the period from 5 September 2024 to 11 September 2024:
| Purchase of shares | |||||
| Date | Number of Shares | Average Price (€) | Highest Price (€) | Lowest Price (€) | Total Amount (€) |
| 5 September 2024 | 1 200 | 36.08 | 36.30 | 35.90 | 43 296 |
| 6 September 2024 | 1 800 | 35.53 | 35.80 | 35.30 | 63 954 |
| 9 September 2024 | 900 | 35.00 | 35.10 | 34.90 | 31 500 |
| 10 September 2024 | 1 200 | 35.03 | 35.30 | 34.80 | 42 036 |
| 11 September 2024 | 2 400 | 34.30 | 34.50 | 33.86 | 82 320 |
| Total | 7 500 | 263 106 | |||
| Sale of shares | |||||
| Date | Number of Shares | Average Price (€) | Highest Price (€) | Lowest Price (€) | Total Amount (€) |
| 5 September 2024 | 600 | 36.55 | 36.60 | 36.50 | 21 930 |
| 6 September 2024 | 300 | 35.80 | 35.80 | 35.80 | 10 740 |
| 9 September 2024 | 900 | 35.43 | 35.50 | 35.40 | 31 887 |
| 10 September 2024 | 0 | 0.00 | 0.00 | 0.00 | 0 |
| 11 September 2024 | 0 | 0.00 | 0.00 | 0.00 | 0 |
| Total | 1 800 | 64 557 | |||
The balance held by Bekaert under the liquidity agreement at the end of the period is 46 418 shares.
On 11 September 2024 after closing of the market, Bekaert holds 1 858 547 own shares, or 3.42% of the total number of the outstanding shares.
This information is also made available on the investor relations pages of our website.
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The 80/20 Institute Introduces an Approach to Expand Margin Without Cutting — by Concentrating on the 20% That Drives Profit
- Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
- QAIAx Clinical Trial: AGI Alternative Sentencing & Reality Pro-Social Dating (Veterans First for America)
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
